Literature DB >> 22398335

Blindness, weakness, and tingling.

Damien Biotti1, Catherine Vignal, Tarek Sharshar, Oliver Gout, Allison N McCoy, Neil R Miller.   

Abstract

A previously healthy 50-year-old man complained of acute bilateral loss of vision over 24 hours associated with tingling of his hands and feet. During the first 48 hours of hospitalization, he evolved quadriplegia, facial diplegia, bulbar palsy, and respiratory distress requiring ventilator assistance. At the same time vision deteriorated to hand motions. Lumbar puncture, electromyography, and clinical findings were all consistent with Guillain-Barré syndrome. The diagnosis of concomitant bilateral optic neuritis was made. Tests for immunological, inflammatory, infectious, or genetic diseases were unremarkable. Within weeks, repeated treatments with intravenous immunoglobulin, plasmapheresis, and high-dose parenteral corticosteroids led to resolution of motor findings, although visual acuity improved only to 20/100 OD and count fingers at 6 feet OS. Guillain-Barré syndrome-associated optic neuritis is rare and may be associated with an underlying Mycoplasma pneumoniae infection.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22398335     DOI: 10.1016/j.survophthal.2011.10.002

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  2 in total

1.  Optic neuritis as a possible phenotype of anti-GQ1b/GT1a antibody syndrome.

Authors:  Damien Biotti; Sophie Boucher; Elodie Ong; Caroline Tilikete; Alain Vighetto
Journal:  J Neurol       Date:  2013-09-06       Impact factor: 4.849

2.  Mitochondrial damage and "plugging" of transport selectively in myelinated, small-diameter axons are major early events in peripheral neuroinflammation.

Authors:  Marija Sajic; Keila Kazue Ida; Ryan Canning; Norman A Gregson; Michael R Duchen; Kenneth J Smith
Journal:  J Neuroinflammation       Date:  2018-02-27       Impact factor: 8.322

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.